Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I did that a long time ago. I do that with all whiney "noise" that contribute no DD.
My simple equation is 8 million ounces of gold worth a speculative 60 in the ground = 480 mil.
480/103 o/s = 4.66
That is my target.
If you read Goldcorps latest 10Q you will see that the silver/copper that came up with the gold gave them a NEGATIVE cost per ounce to process and sell gold.
From their latest release:
"Total cash costs were minus $123 per ounce (net of by-product copper and silver credits) (2005, $52 per ounce)(2)."
http://biz.yahoo.com/iw/060810/0152995.html
We all know that AURC has a LOT of silver and other precious minerals on their properties.
There is so much leeway for lowside disappointment and still have a 10 bagger it is unreal.
All imho and best of luck to all,
Vic
Brent, with the way the markets are acting lately, time seems to be the friend of the most patient amongst us.
Health and prosperity to you,
Vic
Injun, I appreciate your input here. Keep up the good work keeping us informed here.
Let us all know how it all works out net net to you if you try some others as a comparison.
In this tight market, squeezing out an extra 3% per year on cost savings is very worthwhile imo.
Brent, I read all of the filings for the last year and was satisfied as to the share structure and the acreage they were punching holes in. I think it is an excellent spec to put funds into. If they hit a few we're looking good. This is an area that was worked over in the 50's when gas was un-economical to develop. Those economics have shifted dramatically since then.
I don't call CEO's. Whatever they tell me is not on the record and not to be taken seriously imho.
Likewise with investor presentations (dog and pony shows in wall street parlance). Almost always overly optimistic.
The odds here are good if natgas stays above 6.00 mcf. Below that it is marginal imho. With $10 gas this will be a homerun just on the acreage value alone and no drilling imo.
Brent, all I did was enter orders online with Schwab. I put in 5k to buy at .27, .26 and .25 gtc. The first two filled at the prices mentioned before.
If you look at PANNF.PK on yahoo, you'll see it updated at the end of the day to reflect the 10k I bought.
Anyway, I just entered the buy orders on-line for PANNF the same way I would for any "normal" U.S. stock.
If I was heavy into foreign stocks, I would open an account with Interactive Brokers as per Bobwins M.O.
At this time I'm not heavy in foreign issues and choose to pay slightly more for the pink version. I may change my mind in the future though...being that Canada has a tremendous amount of untapped resources.
Injun, I'd say you may be better off on the very lightly traded issues, but that's all. Imo 29.95 is way too high for the majority of orders that do fill on the same day. I'd say 95% of my limit orders fill in one day. I could have an order fill over 3 days and still pay no more than you. I can't even remember an order taking 4 days+ to fill. But then again I like to build a big position in small increments over time. I rarely place 1 big order.
You might consider another low cost broker to trade the more liquid stocks with.
I would put the conversion cost in the 3 to 4% range for PANNF at these levels. About .005 each way in and out, so .01 roundtrip. For a .27 stock that's 3.7%.
SCHW charges me a flat 9.95 per order that fills. No extra charge for multiple fills, no share limits, and no % of principle for stocks below a buck. (Unlike Scottrade who charges 7.00 + 1/2% of principle on sub 1.00 issues).
If a big GTC order is filled over several days, there would be a 9.95 commission for each separate day, just not on multiple fills within each day.
In lightly traded stocks I sometimes get screwed. ie: order to buy 10k at .95 and a mean MM will sell me an odd lot of 67 shares the whole day and I'm stuck with a 9.95 commish on it. That's pretty rare, maybe 2 or 3 times a year out of hundreds of trades.
Using the current exch rate of .889, the .29 CAD prints = .2578 USD. I paid .2627, so I was dinged .0049 on the first lot.
.28 = .2489 USD. I paid .2538 (and filled last 1k for total 5k)which is a ding of .0049 again.
My comission was a flat 9.95 on each trade with Schwab.
So about a half a cent per share rolled into the price I pay for the coversion fee. Not too bad imo.
Bought 5k PANNF at .2627 this morning on a .27 limit. Bought 4k at .2538 on a .26 limit, leaves 1k. Also bidding .25 for 5k gtc.
CPAK down AH on 700 shs. Meaningless imo.
Volume says 733 but I only see 633.
No big whoop either way.
I have a 5.50 buy in for Monday just in case...
I didn't have to call my broker. I entered 5k to buy at .27 and it was accepted right away. (not filled yet).
Maybe I didn't make it clear before. Look on yahoo at PAN.V
http://finance.yahoo.com/q?s=pan.v
They show the bid/ask in Canadian dollars.
It is currently .29/.30
I just multiply the Canadian quote by the exchange rate and that gives me the U.S. dollar equivalent quote.
The exchange rate right now is .89 (I provided a real time currency converter in a previous post.)
.29 x .89 = .26
.30 x .89 = .27
That makes the PANNF quote .26/.27
It's an extra step but but not hard to do.
If it's still not clear to anyone, just ask me, I will be happy to explain further.
Vic
XcelPlus International, Inc., Flextek Dealer and Distributor Networks Continue to Grow at Amazing Pace
Friday August 11, 12:41 pm ET
SALUDA, VA--(MARKET WIRE)--Aug 11, 2006 -- XcelPlus International, Inc. (Other OTC:XLPI.PK - News) anxiously announces their research and development department is in the process of developing the most user-friendly retrofit flex-fuel device currently on the market. Flextek is a bi-fuel converter that works with all multi-port and sequential port fuel injection systems allowing you to choose between fueling up with either Ethanol, gasoline or a mixture of both.
Flextek includes both a conversion system to convert existing gasoline vehicles into flexible-fuel vehicles, and a factory installed flexible-fuel system for OEM flex-fuel vehicles. The conversion systems are the ONLY conversion systems on the market which protect internal engine parts from the effects of burning ethanol.
Kevin Whited, Sales Manager of XcelPlus International, Inc., states, "Our dealer network continues to grow, existing dealers are placing reorders, and we have been contacted by several large wholesalers interested in Flextek." The Flextek kits are being well received in the marketplace. A dealer in South Dakota has moved the largest number of Flextek Kits and reports no complaints, returns, or warranty claims.
XcelPlus International, Inc. is engaging several dealerships in the eastern region of the U.S. and expects to have more dealerships as the price of gasoline rises and the price of E85 decreases. In Pennsylvania, for example, E85 sells for approximately 7% less than regular unleaded gasoline, making the conversion to E85 a sound decision for many consumers, especially those who enjoy the advantages of ethanol's higher octane rating. Ethanol E85 has an octane rating of 110 compared to regular unleaded gasoline's 89 octane, and super grades of gasoline that have 95 octane ratings. E85 is a clear choice for the cost and performance benefits it offers.
XcelPlus International manufactures the Flextek under license from XcelPlus Global Holdings Inc. (Other OTC:EFWO.PK - News), which recently completed a merger with E4 World Corp. XcelPlus Global Holdings owns and controls cutting edge ethanol, chemical, electronic and automotive fuel technologies.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Except for historical information, the forward-looking matters discussed in this news release are subject to certain risks and uncertainties in the Oil and Gas industry which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements including, but not limited to, the Company's liquidity and the ability to obtain financing, the timing of regulatory approvals, uncertainties related to corporate partners or third-parties, competition, and the early stage of exploration and development, as well as other risks indicated from time to time in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.
Contact:
XcelPlus International, Inc. can be contacted by calling:
Brad Novak
Investor Relations
949-661-5780
bnovak@xcelplus.com
http://www.xcelplus.com
XcelPlus International, Inc., Flextek Dealer and Distributor Networks Continue to Grow at Amazing Pace
Friday August 11, 12:41 pm ET
SALUDA, VA--(MARKET WIRE)--Aug 11, 2006 -- XcelPlus International, Inc. (Other OTC:XLPI.PK - News) anxiously announces their research and development department is in the process of developing the most user-friendly retrofit flex-fuel device currently on the market. Flextek is a bi-fuel converter that works with all multi-port and sequential port fuel injection systems allowing you to choose between fueling up with either Ethanol, gasoline or a mixture of both.
Flextek includes both a conversion system to convert existing gasoline vehicles into flexible-fuel vehicles, and a factory installed flexible-fuel system for OEM flex-fuel vehicles. The conversion systems are the ONLY conversion systems on the market which protect internal engine parts from the effects of burning ethanol.
Kevin Whited, Sales Manager of XcelPlus International, Inc., states, "Our dealer network continues to grow, existing dealers are placing reorders, and we have been contacted by several large wholesalers interested in Flextek." The Flextek kits are being well received in the marketplace. A dealer in South Dakota has moved the largest number of Flextek Kits and reports no complaints, returns, or warranty claims.
XcelPlus International, Inc. is engaging several dealerships in the eastern region of the U.S. and expects to have more dealerships as the price of gasoline rises and the price of E85 decreases. In Pennsylvania, for example, E85 sells for approximately 7% less than regular unleaded gasoline, making the conversion to E85 a sound decision for many consumers, especially those who enjoy the advantages of ethanol's higher octane rating. Ethanol E85 has an octane rating of 110 compared to regular unleaded gasoline's 89 octane, and super grades of gasoline that have 95 octane ratings. E85 is a clear choice for the cost and performance benefits it offers.
XcelPlus International manufactures the Flextek under license from XcelPlus Global Holdings Inc. (Other OTC:EFWO.PK - News), which recently completed a merger with E4 World Corp. XcelPlus Global Holdings owns and controls cutting edge ethanol, chemical, electronic and automotive fuel technologies.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Except for historical information, the forward-looking matters discussed in this news release are subject to certain risks and uncertainties in the Oil and Gas industry which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements including, but not limited to, the Company's liquidity and the ability to obtain financing, the timing of regulatory approvals, uncertainties related to corporate partners or third-parties, competition, and the early stage of exploration and development, as well as other risks indicated from time to time in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.
Contact:
XcelPlus International, Inc. can be contacted by calling:
Brad Novak
Investor Relations
949-661-5780
bnovak@xcelplus.com
http://www.xcelplus.com
XcelPlus International, Inc., Flextek Dealer and Distributor Networks Continue to Grow at Amazing Pace
Friday August 11, 12:41 pm ET
SALUDA, VA--(MARKET WIRE)--Aug 11, 2006 -- XcelPlus International, Inc. (Other OTC:XLPI.PK - News) anxiously announces their research and development department is in the process of developing the most user-friendly retrofit flex-fuel device currently on the market. Flextek is a bi-fuel converter that works with all multi-port and sequential port fuel injection systems allowing you to choose between fueling up with either Ethanol, gasoline or a mixture of both.
Flextek includes both a conversion system to convert existing gasoline vehicles into flexible-fuel vehicles, and a factory installed flexible-fuel system for OEM flex-fuel vehicles. The conversion systems are the ONLY conversion systems on the market which protect internal engine parts from the effects of burning ethanol.
Kevin Whited, Sales Manager of XcelPlus International, Inc., states, "Our dealer network continues to grow, existing dealers are placing reorders, and we have been contacted by several large wholesalers interested in Flextek." The Flextek kits are being well received in the marketplace. A dealer in South Dakota has moved the largest number of Flextek Kits and reports no complaints, returns, or warranty claims.
XcelPlus International, Inc. is engaging several dealerships in the eastern region of the U.S. and expects to have more dealerships as the price of gasoline rises and the price of E85 decreases. In Pennsylvania, for example, E85 sells for approximately 7% less than regular unleaded gasoline, making the conversion to E85 a sound decision for many consumers, especially those who enjoy the advantages of ethanol's higher octane rating. Ethanol E85 has an octane rating of 110 compared to regular unleaded gasoline's 89 octane, and super grades of gasoline that have 95 octane ratings. E85 is a clear choice for the cost and performance benefits it offers.
XcelPlus International manufactures the Flextek under license from XcelPlus Global Holdings Inc. (Other OTC:EFWO.PK - News), which recently completed a merger with E4 World Corp. XcelPlus Global Holdings owns and controls cutting edge ethanol, chemical, electronic and automotive fuel technologies.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Except for historical information, the forward-looking matters discussed in this news release are subject to certain risks and uncertainties in the Oil and Gas industry which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements including, but not limited to, the Company's liquidity and the ability to obtain financing, the timing of regulatory approvals, uncertainties related to corporate partners or third-parties, competition, and the early stage of exploration and development, as well as other risks indicated from time to time in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.
Contact:
XcelPlus International, Inc. can be contacted by calling:
Brad Novak
Investor Relations
949-661-5780
bnovak@xcelplus.com
http://www.xcelplus.com
Brent, I WAS talking about buying PANNF. I don't see a quote on PANNF on Scottrade or elsewhere. Only the last sale.
Often times the pink U.S. version of a Canadian stock only updates once a day or less.
If the Canadian quote changed up or down quite a bit, you might not know it looking only at PANNF.
I trade the U.S. pink version of other Can stocks (HBM.TO/HBMFF, SHY.V/SHEYF) and always look at the more active Can quote first and apply the conversion to USD for the pink version.
Another advantage of watching PAN.V also (on yahoo)is that news releases will show up there and not at PANNF.PK.
Hope this helps,
Vic
For free real time currency converter this is the one I use:
http://www.xe.com/ucc/
Brent, thanks for the heads up on Panterra. For those wanting to buy, I suggest looking at PAN.V for the canadian quote and multiply that by the USD/CAD exchange rate to determine the proper bid for PANNF.
http://finance.yahoo.com/q?s=PAN.V
The current CAD bid is (15 min delay) .29 (offered at .335)
The current exch rate is .894.
.29 x .894 = .259. Therefore .26 would be the appropriate bid for PANNF at this moment.
If wanting to take the offering, then .335 x .894 = .299. A hight limit of .30 would be appropriate for PANNF at this moment.
Good luck to all,
Vic
R59, Thanks and good luck. BTW, KMG is the operator of the Norman Prospect.
CPE guided lower for the full year from 70-75 MMcfe/d previous guidance to 58-62 MMcfe/d on new guidance.
Q3 natgas expected to be flat at 2.6 to 2.8 BCF.
Q3 oil expected to be 350 - 375 Mbbls vs 443 Mbbls in q2.
A lot of production (mostly gas) that was expected to come online in late q2 and early q3 is now deferred to late q3 and early q4. Q3 will look weak sequentially but Q4 should kick butt.
Howard Weil yesterday downgraded from Hold to Sell with a target price of 18 vs 23 previously.
The deep Norman Prospect will spud in 30 days or so. CPE has 5% WI and the potential is 200-500 MMbls. That would be 10 to 25 million bbls for CPE if it hits.
I am a fairly aggressive buyer at these levels. As the Norman Prospect gets spudded and starts reaching TD later in the year (24,000 feet), it should generate some good buzz.
With NAV of about 30, this is a keeper at these levels and lower imo.
It will end up the other way around eventually imo.
Shareholders equity jumped 31.5 mil. Now 121.2 mil vs 89.7 mil at 3/31/06.
Production increased to 8.1 MMcfe/d...the highest in over a year.
Unrealized income of 28.4 mil on the balance sheet for GED holdings. That is future income on the EPS anytime HEC sells some of their 11.9 million shares of GED.
The deconsolidation of Global has confused many investors and caused the sell-off imo.
It should go back up soon imho.
You're reading it backwards. EPS was 0 for 3 months ended 6/30/06 vs .07 as reported in 2005.
Jesty,
I look at the SEC filings for the latest o/s and info that is published.
Ronnie D called the transfer agent to get the update. I just compared the two and the dates.
Here are all the SEC filings for UPDA if you want to wade through a few.
http://www.sec.gov/cgi-bin/browse-edgar?company=universal+property&CIK=&filenum=&State=&....
If it doesn't come up for you, type in "universal property" in the top box for "company name".
Just play with it and you'll figure it out after a while.
Good luck,
Vic
From the last 10Q:
OUTSTANDING AT MAY 10, 2006
Common stock - par value $0.001 128,194,806
Per Ronnie D call to TA:
8/1/06 o/s = 190,441,306
An increase of 62,246,500 shares in 80 days.
And some of you wonder why this stock won't rally?
Thanks Ronnie,
Vic
I updated my last reply with an excerpt from this:
http://www.investorshub.com/boards/complex_terms.asp
But you also have to realize that a hedge fund with hundreds of millions to play with...well, it would be no big deal for them to buy 5 to 10 cheap computers with a different alias on each one and pump or bash a stock if big bucks are at stake.
Jmho.
S/R...There is a 1 account limit for all users of IHUB, free or paid. If they catch multiple accounts, they delete all but the original and throw the original in jail until they promise not to do it again.
This is part of the user agreement when you first sign up:
"By accepting the User Agreement, you warrant that you have no other registration(s) with iHub. You also agree to maintain only one active registration with iHub. Failure to follow the User Agreement will result in your immediate termination from iHub. If you forget your user name or password, please contact: support@investorshub.com"
Some may get around it with multiple computers, but only once
with each computer.
You have to admit, it's a lot better here than yahoo or RB.
Sounds like they could lower the charges to paid members and make more money off the volume. IE: paid = .35 vs free .04...cut paid fees in half it's still .17 vs .04 and if paid triples as a result it's a win win.
They might get the occasional PR spike out of it, but that's about all. No profits are in sight for 2 years.
They have 24 months remaining on the aggreement with Fusion Capital, Fusion to buy $15 mil worth of stock at the average of lowest 3 days of preceding 12. Fusion cannot buy below .50...so that is the target range for them to drive the pps down to for maximum bang for the hedge fund buck.
Insiders recently issued themselves options on 6 million shares at .85 good until 2016.
The cost to MSU was much smaller than I thought it would be. Only $1000 up front. You can find the milestone payments and royalty schedule here:
http://www.sec.gov/Archives/edgar/data/1054274/000105427406000022/exhibit101licenseagreement.htm
As you can see, the milestone payments are quite small and royalties only 2.5%.
I would be inclined to accumualte below .75 lightly and heavy below .60 and sell 75% on all spikes above 1.00 and keep a 25% core just in case it does a moonshot.
Good luck to you,
Vic
I got an email blast that I posted on another board yesterday.
HPLF.OB being touted by Kenneth Coleman as a potential 800% gainer in an email blast via Bernie Schaefer I received today.
Some excerpts:
>>>Bird flu – the “new oil & gas” for investors…
Looking for quick gains?
The bird flu boom could give you 800% or more in just weeks…
Bird flu stocks are skyrocketing.
Top choice: HepaLife Technologies (HPLF).
Less than 45 days ago this undiscovered company picked up patents for the key bird flu vaccine technology.
Amazingly, its share price is still around $1.00. Buy today and you could potentially see gains of 800% or more as it takes off.
Bird flu is one of the biggest crisis stories in years. And this is just the beginning. Buy this vaccine developer today and you could potentially be holding the best, most profitable buy you've made in years.
I believe the time is right for HPLF to skyrocket. Here's why….
As news of the global bird flu scare picked up going into last winter's flu season, share prices of vaccine makers skyrocketed. One company shot up more than 800%. Another went from $3.82 to over $22 in about the same time.
In January, after another news surge, a third flu-related company gained more than 120% in 13 days. Yet another zoomed from under $1 to more than $4 in less than 90 days during the same time.
If you think that’s impressive, wait till bird flu hits the U.S., as experts think it will sometime this winter. The story will dominate headlines, and HPLF’s share prices could skyrocket to astronomical gains. I’m projecting 800% or more, based on what I’ve already seen in the industry, and the fact that the problem will become worse and the headlines will become louder.
I’ve had my eye on HPLF for a while. I’ve watched their science progress, their company mature. And about 45 days ago, when they picked up the patents for a very promising bird flu vaccine, I knew it was time to buy.
HepaLife has several big advantages over other companies developing flu vaccines. First of all is the technology itself.
Instead of the problem-ridden egg culture production method, HPLF’s patented technology relies on a totally new and improved method. It is the first immortal chicken embryo cell line that is virus-free and contact-inhibited.
That means that the cells grow continuously, instead of needing to be introduced into a host egg every time the vaccine is produced. There is less risk of foreign contaminants such as Salmonella, Newcastle disease, or reovirus that frequently plague current production methods. It also allows a more rapid response to new influenza strains that might arise or become a threat. An additional advantage is that individuals with allergies to eggs, who cannot be vacinnated with current vaccines, could receive a cell culture based product.
The result…
Lower production costs
Faster production time
Less risk of vaccine contamination
Less risk of allergic reaction
Another big advantage for HepaLife is that it is one of the new breed of “virtual” companies.
In today’s high-cost environment, the smartest companies are reducing overhead and speeding time to market by subcontracting everything from product development to production.
What it means to you is that HPLF has just a fraction of the costs that burden many a company’s cost to earnings ratios. That lowers the company’s risk by a huge degree. And so it lowers your risk as well.
HepaLife Technologies (HPLF) could give 800% returns within 8-12 weeks when bird flu hits the headlines again
Let's take a look at the facts for HPLF again:
HPLF just entered the bird flu vaccine market. Investors haven’t discovered it yet and share price is still about $1
HPLF has the one of the most advanced technologies for vaccine production, protected by five patents
Shares in crisis-boom companies rise on headlines. Bird flu headlines are becoming more pressing, more frequent
I expect HPLF to skyrocket as soon as the next phase of the bird flu scare hits and investors discover the company
Short term gains could be 800% or more for HPLF
But he'res the kicker….
HepaLife’s vaccine technology is so breakthrough, so important that longterm, HPLF could potentially be one of the most profitable invest-ments of your life.
Here’s to your successful investing!
Sincerely,
Ken Coleman
Publisher & Editor, The Investment-Tracker<<<
Full Disclusure: I have never owned HPLF and do not own it at this time.
Vic
S/R... well said. It's the same ol same ol..."you get what you pay for".
I was a freebie many months to see if I even liked this site. I am satisfied that the good far outweighs the bad (Yahoo and RB to name two).
But that's just my humble opinion.
2create is the better choice to answer that.
GBMR I will be more prone to trade, and NNRF to hold long term.
I buy both. My last 2 buys in GBMR were 10k at .05 and 10k at .041. Next level about .036 if...
GBMR total = 125k shares.
NNRF total = 12500 shares.
Dollar wise, I allocate twice as much to NNRF.
HPLF.OB being touted by Kenneth Coleman as a potential 800% gainer in an email blast via Bernie Schaefer I received today.
Some excerpts:
>>>Bird flu – the “new oil & gas” for investors…
Looking for quick gains?
The bird flu boom could give you 800% or more in just weeks…
Bird flu stocks are skyrocketing.
Top choice: HepaLife Technologies (HPLF).
Less than 45 days ago this undiscovered company picked up patents for the key bird flu vaccine technology.
Amazingly, its share price is still around $1.00. Buy today and you could potentially see gains of 800% or more as it takes off.
Bird flu is one of the biggest crisis stories in years. And this is just the beginning. Buy this vaccine developer today and you could potentially be holding the best, most profitable buy you've made in years.
I believe the time is right for HPLF to skyrocket. Here's why….
As news of the global bird flu scare picked up going into last winter's flu season, share prices of vaccine makers skyrocketed. One company shot up more than 800%. Another went from $3.82 to over $22 in about the same time.
In January, after another news surge, a third flu-related company gained more than 120% in 13 days. Yet another zoomed from under $1 to more than $4 in less than 90 days during the same time.
If you think that’s impressive, wait till bird flu hits the U.S., as experts think it will sometime this winter. The story will dominate headlines, and HPLF’s share prices could skyrocket to astronomical gains. I’m projecting 800% or more, based on what I’ve already seen in the industry, and the fact that the problem will become worse and the headlines will become louder.
I’ve had my eye on HPLF for a while. I’ve watched their science progress, their company mature. And about 45 days ago, when they picked up the patents for a very promising bird flu vaccine, I knew it was time to buy.
HepaLife has several big advantages over other companies developing flu vaccines. First of all is the technology itself.
Instead of the problem-ridden egg culture production method, HPLF’s patented technology relies on a totally new and improved method. It is the first immortal chicken embryo cell line that is virus-free and contact-inhibited.
That means that the cells grow continuously, instead of needing to be introduced into a host egg every time the vaccine is produced. There is less risk of foreign contaminants such as Salmonella, Newcastle disease, or reovirus that frequently plague current production methods. It also allows a more rapid response to new influenza strains that might arise or become a threat. An additional advantage is that individuals with allergies to eggs, who cannot be vacinnated with current vaccines, could receive a cell culture based product.
The result…
Lower production costs
Faster production time
Less risk of vaccine contamination
Less risk of allergic reaction
Another big advantage for HepaLife is that it is one of the new breed of “virtual” companies.
In today’s high-cost environment, the smartest companies are reducing overhead and speeding time to market by subcontracting everything from product development to production.
What it means to you is that HPLF has just a fraction of the costs that burden many a company’s cost to earnings ratios. That lowers the company’s risk by a huge degree. And so it lowers your risk as well.
HepaLife Technologies (HPLF) could give 800% returns within 8-12 weeks when bird flu hits the headlines again
Let's take a look at the facts for HPLF again:
HPLF just entered the bird flu vaccine market. Investors haven’t discovered it yet and share price is still about $1
HPLF has the one of the most advanced technologies for vaccine production, protected by five patents
Shares in crisis-boom companies rise on headlines. Bird flu headlines are becoming more pressing, more frequent
I expect HPLF to skyrocket as soon as the next phase of the bird flu scare hits and investors discover the company
Short term gains could be 800% or more for HPLF
But he'res the kicker….
HepaLife’s vaccine technology is so breakthrough, so important that longterm, HPLF could potentially be one of the most profitable invest-ments of your life.
Here’s to your successful investing!
Sincerely,
Ken Coleman
Publisher & Editor, The Investment-Tracker<<<
Full Disclusure: I have never owned HPLF and do not own it at this time.
Vic
Thanks nagolf,
I usually screen for the best balance sheets of stocks under $5 that have fallen at least 50% from 52 week high. Try to remove the belly up factor as a starting point before narrowing the list down.
Maybe I'm overthinking it!
What a joke. Utah is not banning the practice...just requiring reporting of it.
This proves the problem is more pervasive than many think imho.
R59,
Fantastic work.
Combining that with the January effect, it would be interesting to see the results of 52 week lows in December only and the subsequent rebound 1 month, 2 months, and 3 months later.
Rook, I don't know if it's possible to get exact data at this time. The buyins.net article inferred that you take the published number and multiply by 20 to get a minimum actual.
AURC reported 65k x 20 = 1.3 million shares short a "probable" minimum.
If you look at this part of Reg SHO:
>> 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. <<
AURC has o/s 103 million. .005x103Mil=515,000 MINIMUM shares short to be on the SHO list!
So for the otcbb short report to say 65,411 shares is a joke. It is useless information.